{
  "first_published_at": "2013-09-09", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314895", 
  "title": "Filgrastim and pegfilgrastim: risk of potentially life-threatening capillary leak syndrome", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\", \"haematology\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\", \"Haematology\"]}", 
  "_document_number": 56, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer", 
    "haematology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Filgrastim and pegfilgrastim: risk of potentially life-threatening capillary leak syndrome</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br><p>Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Episodes varied in severity and frequency. CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration, and may be fatal unless promptly diagnosed and managed.</p>\n\nPrescribers should monitor patients and healthy donors for signs and symptoms of CLS, and should give standard symptomatic treatment immediately if symptoms occur. Advise patients to seek medical attention immediately if they experience symptoms of CLS<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Background</strong></p>\n\n<p>Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are recombinant granulocyte colony-stimulating factors (G-CSF) used to stimulate the proliferation and differentiation of granulocytes, especially polymorphonuclear, in various forms of neutropenia induced by chemotherapy. Filgrastim is also used to help release blood stem cells from the bone marrow of healthy donors.</p>\n\n<p>A review of filgrastim and pegfilgrastim was triggered by postmarketing reports of capillary leak syndrome (CLS). CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration.</p>\n\n<p><strong>Review of the signal</strong></p>\n\n<p>CLS has been reported in patients with cancer undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation who were receiving filgrastim or pegfilgrastim. Reports have generally involved people with advanced malignant disease, sepsis, those taking multiple chemotherapy medicines, or those undergoing apheresis. The mechanism of CLS remains unclear.</p>\n\n<p><em>Filgrastim</em></p>\n\n<p>For filgrastim, 34 postmarketing reports of CLS were received worldwide between April 1991 and August 2012, including five reports received via the Yellow Card Scheme. Of these, one case concerned a healthy donor undergoing stem-cell mobilisation and apheresis. In 12 cases, symptoms of CLS improved or recovered with supportive or corticosteroid treatment and discontinuation of filgrastim. In most cases, CLS symptoms occurred after the first dose of filgrastim. In two cases, symptoms occurred after the first dose and then reoccurred during the second. Six cases of CLS had a fatal outcome.</p>\n\n<p><em>Pegfilgrastim</em></p>\n\n<p>For pegfilgrastim, four postmarketing reports of CLS were received worldwide between August 2002 and August 2012. CLS symptoms appeared after the second dose in two cases. In one of these cases, CLS occurred 1 day after pegfilgrastim, suggesting a temporal association. In another case, the patient had a fatal outcome from CLS.</p>\n\n<p><strong>Conclusions</strong></p>\n\n<p>The postmarketing adverse reaction reports provide good evidence of a temporal and causal association between filgrastim or pegfilgrastim treatment and CLS. However, the benefits of filgrastim and pegfilgrastim continue to outweigh the risks. Healthcare professionals should note the following to help manage and minimise the risk of CLS:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Closely monitor all patients and healthy donors for CLS symptoms, which commonly have rapid onset. Symptoms include: generalised body swelling; puffiness (which may be associated with less-frequent urination); difficulty breathing; abdominal swelling; and tiredness</li>\n\n<li>Give standard symptomatic treatment immediately if symptoms occur</li>\n\n<li>Advise patients and healthy donors to contact their doctor immediately if they develop CLS symptoms</li>\n\n<li>Any suspected adverse reactions to filgrastim or pegfilgrastim should be reported to us on a <a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">Yellow Card</a></li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Minutes from the <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2012/12/WC500135712.pdf\" target=\"_blank\">meeting of the Pharmacovigilance Risk Assessment Committee, October 2012</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643\" target=\"_blank\">Letter for healthcare professionals sent August 2013</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update August 2013 volume 7, issue 1: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Background</strong></p>\n\n<p>Filgrastim (Neupogen) and pegfilgrastim (Neulasta) are recombinant granulocyte colony-stimulating factors (G-CSF) used to stimulate the proliferation and differentiation of granulocytes, especially polymorphonuclear, in various forms of neutropenia induced by chemotherapy. Filgrastim is also used to help release blood stem cells from the bone marrow of healthy donors.</p>\n\n<p>A review of filgrastim and pegfilgrastim was triggered by postmarketing reports of capillary leak syndrome (CLS). CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration.</p>\n\n<p><strong>Review of the signal</strong></p>\n\n<p>CLS has been reported in patients with cancer undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation who were receiving filgrastim or pegfilgrastim. Reports have generally involved people with advanced malignant disease, sepsis, those taking multiple chemotherapy medicines, or those undergoing apheresis. The mechanism of CLS remains unclear.</p>\n\n<p><em>Filgrastim</em></p>\n\n<p>For filgrastim, 34 postmarketing reports of CLS were received worldwide between April 1991 and August 2012, including five reports received via the Yellow Card Scheme. Of these, one case concerned a healthy donor undergoing stem-cell mobilisation and apheresis. In 12 cases, symptoms of CLS improved or recovered with supportive or corticosteroid treatment and discontinuation of filgrastim. In most cases, CLS symptoms occurred after the first dose of filgrastim. In two cases, symptoms occurred after the first dose and then reoccurred during the second. Six cases of CLS had a fatal outcome.</p>\n\n<p><em>Pegfilgrastim</em></p>\n\n<p>For pegfilgrastim, four postmarketing reports of CLS were received worldwide between August 2002 and August 2012. CLS symptoms appeared after the second dose in two cases. In one of these cases, CLS occurred 1 day after pegfilgrastim, suggesting a temporal association. In another case, the patient had a fatal outcome from CLS.</p>\n\n<p><strong>Conclusions</strong></p>\n\n<p>The postmarketing adverse reaction reports provide good evidence of a temporal and causal association between filgrastim or pegfilgrastim treatment and CLS. However, the benefits of filgrastim and pegfilgrastim continue to outweigh the risks. Healthcare professionals should note the following to help manage and minimise the risk of CLS:</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Closely monitor all patients and healthy donors for CLS symptoms, which commonly have rapid onset. Symptoms include: generalised body swelling; puffiness (which may be associated with less-frequent urination); difficulty breathing; abdominal swelling; and tiredness</li>\n\n<li>Give standard symptomatic treatment immediately if symptoms occur</li>\n\n<li>Advise patients and healthy donors to contact their doctor immediately if they develop CLS symptoms</li>\n\n<li>Any suspected adverse reactions to filgrastim or pegfilgrastim should be reported to us on a <a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">Yellow Card</a></li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>Minutes from the <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2012/12/WC500135712.pdf\" target=\"_blank\">meeting of the Pharmacovigilance Risk Assessment Committee, October 2012</a></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643\" target=\"_blank\">Letter for healthcare professionals sent August 2013</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update August 2013 volume 7, issue 1: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-09-01", 
  "date_last_modified": "2013-09-09", 
  "_assets": [], 
  "_item_id": 56, 
  "summary": "Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Episodes varied in severity and frequency. CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration, and may be fatal unless promptly diagnosed and managed.\n\nPrescribers should monitor patients and healthy donors for signs and symptoms of CLS, and should give standard symptomatic treatment immediately if symptoms occur. Advise patients to seek medical attention immediately if they experience symptoms of CLS", 
  "body": "Article date: September 2013\n\nBackground\n\nFilgrastim (Neupogen) and pegfilgrastim (Neulasta) are recombinant granulocyte colony-stimulating factors (G-CSF) used to stimulate the proliferation and differentiation of granulocytes, especially polymorphonuclear, in various forms of neutropenia induced by chemotherapy. Filgrastim is also used to help release blood stem cells from the bone marrow of healthy donors.\n\nA review of filgrastim and pegfilgrastim was triggered by postmarketing reports of capillary leak syndrome (CLS). CLS is characterised by: hypotension and oedema; hypoalbuminaemia; and haemoconcentration.\n\nReview of the signal\n\nCLS has been reported in patients with cancer undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation who were receiving filgrastim or pegfilgrastim. Reports have generally involved people with advanced malignant disease, sepsis, those taking multiple chemotherapy medicines, or those undergoing apheresis. The mechanism of CLS remains unclear.\n\nFilgrastim\n\nFor filgrastim, 34 postmarketing reports of CLS were received worldwide between April 1991 and August 2012, including five reports received via the Yellow Card Scheme. Of these, one case concerned a healthy donor undergoing stem-cell mobilisation and apheresis. In 12 cases, symptoms of CLS improved or recovered with supportive or corticosteroid treatment and discontinuation of filgrastim. In most cases, CLS symptoms occurred after the first dose of filgrastim. In two cases, symptoms occurred after the first dose and then reoccurred during the second. Six cases of CLS had a fatal outcome.\n\nPegfilgrastim\n\nFor pegfilgrastim, four postmarketing reports of CLS were received worldwide between August 2002 and August 2012. CLS symptoms appeared after the second dose in two cases. In one of these cases, CLS occurred 1 day after pegfilgrastim, suggesting a temporal association. In another case, the patient had a fatal outcome from CLS.\n\nConclusions\n\nThe postmarketing adverse reaction reports provide good evidence of a temporal and causal association between filgrastim or pegfilgrastim treatment and CLS. However, the benefits of filgrastim and pegfilgrastim continue to outweigh the risks. Healthcare professionals should note the following to help manage and minimise the risk of CLS:\n\nAdvice for healthcare professionals:  \n  \n  * Closely monitor all patients and healthy donors for CLS symptoms, which commonly have rapid onset. Symptoms include: generalised body swelling; puffiness (which may be associated with less-frequent urination); difficulty breathing; abdominal swelling; and tiredness  \n  * Give standard symptomatic treatment immediately if symptoms occur  \n  * Advise patients and healthy donors to contact their doctor immediately if they develop CLS symptoms  \n  * Any suspected adverse reactions to filgrastim or pegfilgrastim should be reported to us on a [Yellow Card](http://www.mhra.gov.uk/yellowcard)  \n  \nFurther information:\n\nMinutes from the [meeting of the Pharmacovigilance Risk Assessment Committee, October 2012](http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2012/12/WC500135712.pdf)\n\n[Letter for healthcare professionals sent August 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643)\n\n \n\nArticle citation: Drug Safety Update August 2013 volume 7, issue 1: A1.\n"
}